Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases
Other content recommended for you
- Should rare diseases get special treatment?
- Patent pools: an idea whose time has come
- Don’t worry about the drug industry’s profits when considering a waiver on covid-19 intellectual property rights
- US incentive scheme for neglected diseases: a good idea gone wrong?
- New deal from the World Trade Organisation
- Ethical issues in funding research and development of drugs for neglected tropical diseases
- Public sector financial support for late stage discovery of new drugs in the United States: cohort study
- Ethical issues in funding orphan drug research and development
- Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
- Prioritising neglected diseases related to poverty